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Abstract
Glioma are glia-derived brain tumors that have poor prognosis. This thesis project tests Tyrosine Kinase
Inhibitor drugs that have shown promise during an ongoing chemical drug screen on an alternate oncogenic
pathway. In the ongoing chemical screen, tumors were induced in Drosophila melanogaster by expressing
PtenRNAi to eliminate the tumor suppressor gene, Pten, which negatively regulates the Pi3K pathway. For
this thesis project, tumors will be induced through constitutively activating the EGFR (epidermal growth
factor receptor) through the Pi3K pathway. Therefore, these two projects individually look at two different
types of glioma and aim to determine if certain drugs show promise on more than one type of glioma. A
series of crosses over the course of three generations is performed to balance chromosomes of the flies and
result in the genotype with the EGFR mutation. Data collection includes exposing these flies to the specific
tyrosine kinase inhibitor drugs when added to their food. Larvae is collected, dissected to obtain the brains,
washed and mounted on microscope slides after 2 and 3 days of exposure to the drugs. Images are taken of
the mounted brains for further data analysis. In order to conclude if these drugs showed similar promise as
in the existing chemical screen, images will be examined for enhancement, suppression or no effect in
comparison to Pi3k; Repo control brains of flies left untreated.
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Introduction
Today, cancer is still one of the leading causes of death and results in 8.2 million
people deaths a year (National Cancer Institute, 2018). Of these deaths, about 13,000 of
these cancer deaths are from brain cancer, and specifically 9,100 suffered from
aggressive form of glioma. Glioma are glia-derived brain tumors with poor prognosis.
Current treatments for glioma include surgery, chemotherapy and radiotherapy (John’s
Hopkins Medicine). While these treatments target tumorous cells, these treatments also
effect healthy cells. Therefore, these patients’ lives are usually only extended by a few
months (Brennan et al., 2013). The lack of life-extending treatments calls for research in
treatments that can provide better prognosis.
There are a variety of mutations that can lead to the development of glioblastoma.
Some mutations are specific to glioblastoma, while others are common cancer mutations.
TP53 and PTEN are common cancer mutations (Liu, 2016). PTEN is a tumor suppressor
gene and these mutations usually result in the loss of function. In addition, point
mutations in EGFR is also common. EGFR mutations result in EGFR amplification.
Other common mutations found in glioblastoma include Pi3KCA and Pi3KR1, NF1, RB1,
and IDH1 (Liu 2016). Many of these genes regulate cell signaling involving cell
proliferation and survival (Liu 2016).
The development of glioma is important in understanding the prognosis of this
type of cancer and the need for better treatment. As previously mentioned, glioma are
glia-derived brain tumors. Glia cells are products down the line of neuroblast cell division
(Figure 1). Neuroblasts undergo asymmetric cell division (Homem et al., 2012). In
Drosophila, division results in two daughter cells, either a ganglion mother cell or
another neuroblast that will undergo further division into two more daughter cells.
Ganglion mother cells then divide into a neuron and glia cell. In humans, neuroblast
division is more complex, involving the transit amplification of interneurons. Using
Drosophila as a model organism is beneficial due to their simpler central nervous system
and neuroblast division. This division can be important in understanding the development
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of glioma depending on the rounds of cell division in development. The amount of
neuroblasts can be determined in Miranda staining, whereas the amount of Ganglion
Mother cells can be determined through Prospero staining (Brody, 1996). These two
stains have been beneficial in analyzing the production of tumors in model organisms.
Drosophila melanogaster is the model organism used in this experiment and has
been a pivotal model organism in scientific research. This model organism is beneficial in
scientific research due to its accessibility, ease in maintaining, and their short life spans
(Figure 2). Drosophila has led to many scientific discoveries and has been used in
studying many diseases such as cancer, cardiovascular disease, neurological diseases and
diseases related to the immune system (Fortini et al., 2000). Another important aspect of
Drosophila are the similarities their genomes share with humans. 70% of human diseaselinked genes are seen in Drosophila (Chien et al, 2002; Hirth, 2010; Pandley and Nichols,
2011; Read, 2011), as well as important cellular signaling pathways such as Wnt, Hippo,
Notch, Pi3K and EGFR (Read, 2011; Tickoo and Russell, 2002).
The signaling pathways mentioned are important in cellular mechanisms such as
growth, development and cell proliferation (Figure 3). When these signaling pathways
are mutated or do not operate as they should, cancer can result. Glioblastomas are
associated with many different mutations in these oncogenic pathways (Phillips et al,
2006; Verhaak et al., 2002). Many glioblastomas include mutation that leads to
overexpression of receptors of tyrosine kinases like EGFR (Read, 2013). Tyrosine
kinases are important in signaling cascades in cells that activate specific genes (Paul et
al., 2004). In normal functioning cells, tyrosine kinases like EGFR are important for
cellular functions. For example, cell proliferation is promoted (Huang et al., 2007).
However, in mutant EGFR, the kinase is constitutively active and therefore, constantly
stimulates RAS that promotes migration and blocks apoptosis leading to tumor
development (Boockvar et al., 2003). However, glioma requires activation of two of these
genetic pathways to result in cancer. In humans, the most common oncogenic pathways
activated are the co-activation of EGFR and Pi3K (Raizer, 2011). Modeling this coactivation in Drosophila to induce glioblastoma is the critical first step in this thesis
project. The effectiveness of specific tyrosine kinase inhibitor drugs that had showed
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interesting results on glioma induced by a Pten mutation through the RAS pathway are
tested on a different mutation for this thesis project. The previous drug screen focused on
glioma induced through a negative mutation, while this project focuses on an EGFR
mutation that is constitutively active.
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Figure 1
Neuroblast stem cells undergo asymmetric cell division. They can divide to
self-renew into another neuroblast or into ganglion mother cells (GMC) that
further divide into a glia cell or neuron. Each cell type can be identified based
on biomarkers like Miranda for Neuroblasts and Prospero for GMC.
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Figure 2 (Maynard, 2009)
In this figure, the life cycle of Drosophila is shown,
along with the timeframe of each stage. The short
lifespan from embryo, larvae and adult provides
advantages in the research field to complete many
trials or experiments in a short amount of time.
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Figure 3 (Rybak, 2014)
These signaling pathways including Ras, Pi3K, and STAT3 converge and act directly
or cross actively to mediate tumorigenesis. If mutations in these pathways or present
receptors are found, tumors such as GBM can result.
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Methods
Drosophila crosses to generate Pi3K EGFRλtop glioma:
The overall drug screen consists of seven steps and the drugs tested throughout
this project were P1A9 and P1G10. As mentioned, modeling the co-activation of the
EGFR and Pi3k pathway is the critical first step in inducing glioblastoma in the model
organism. The co-activation of these pathways required a series of steps over the course
of three generations of Drosophila. This is accomplished with balancer chromosomes.
Balancer chromosomes are specific stocks in Drosophila that are rearranged
chromosomes that can be used to maintain a mutant genotype or help in complex
genotype construction (Miller et al., 2018). However, lethality is a possible issue with
these oncogenic mutations and can cause issues determining crossing schemes to obtain
specific genotypes. For this project, three generations of crosses were completed to obtain
the final genotype for the Pi3k; Repo stock (Figure 4). In each generation, female virgins
are collected and used in the next step. Recombination, or genetic exchange between
chromosomes, occurs in female flies (John et al., 2016). Using female virgins eliminates
the risk of recombination when trying to obtain a specific genotype. Once this genotype
was obtained, the stock was crossed with EGFRλtop resulting in the final cross with
induced glioma. Once glioma was successfully induced in Drosophila, the final cross and
final balanced stocks were maintained with a 2:1 female to male ratio to result in
maximal egg production for data collection.

Drug Screen:
Larvae from control stocks and the Pi3K; Repo X EGFRλtop cross are collected on
day 3 of their life span when they are in their early third instar stage (Figure 2). Third
instar larvae are added to food that has been infused with the specific tyrosine kinase
inhibitor chemicals. The larvae are exposed to the inhibitor drugs for an additional 3 days
and are collected again at day 5 and 6 of age. When collected after exposure, the larvae
are dissected to obtain the brain and ventral cord. Before imaging, the dissection is
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successfully prepared. Following dissection, larvae samples are fixed for 20 minutes in
150 microliters of PBS and 50 microliters of 16% PFA. The larvae samples are then
washed for 10 minutes in 1mL of PBS-T. The sample is then mounted onto microscope
slides for imaging and are protected and secured by Vectashield (Vector Labs, USA).
Imaging is completed using fluorescent microscopy for both the control stocks and main
cross.

Immunochemistry:
In addition to images following drug exposure, Miranda staining is also
completed in attempts to explain tumor progression. Larvae was dissected and prepared
similarly to the samples prepared after drug exposure. Following fixing, Miranda
antibody 1:200 dilution is added to the sample and incubated overnight at 4°C. The
primary antibody is removed, and the samples washed with PBST, then incubated with
the appropriate secondary antibody fused to a fluorophore (e.g. anti-mouse Cy3). After
2h the samples are washed for a series of 3 rounds of 10 minute washes. The stained
brains are mounted and protected with Vectashield (Vector Labs, USA). The stained
slides are imaged using confocal microscopy (Olympus Fluoview 3000).

Quantification of data:
Quantification of data was completed by analyzing the central brain region, or the
CBR. The CBR is located between the two occipital disks and ventral cord (Figure 5).
The width of the CBR was measured in pixels. These widths were then compared
between the crosses and controls exposed to drug treatment to determine the effects.
Suppression was seen if the size of the CBR decreased in comparison to the cross
untreated and is more similar to the size of the control. Likewise, enhancement was
observed in the width of the CBR is greater than the cross untreated and larger than the
control.

9

Figure 4
A series of crosses were designed with balancer chromosomes to obtain
the wanted genotype for Pi3k; Repo to induce tumor when crossed with
EGFRλtop. This was accomplished over three generations.
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Figure 5
The CBR is located in between the two occipital
lobes of the brain. The ventral nerve cord is the
posterior part of the Drosophila brain.
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Results
The Pi3K EGFRλtop model of glioma growth:
The Pi3k EGFRλtop model of glioma growth showed similar results when
compared to the Pteni; RasV12 model. In both models, there was a significant increase in
size of the CBR when the cross was compared to the control. In Figure 6, this significant
difference is observed. In both studies, the controls showed a CBR of 145-170 pixels in
width. In both mutations, the crosses showed an enhanced CBR of 230 pixels in width.
Following the completion of the cross scheme for co-activation of Pi3K and
EGFR and prior to drug exposure, control images were completed and analyzed for both
the control stock and the cross (Figure 7C). The area examined for analysis was the
central brain region (CBR). This region was analyzed by determining the average width
of the central brain region in pixels for both the control stock and co-activated cross
(Figure 7B). On average, the control stock showed CBR of 455.50 pixels, whereas the coactivated cross showed a larger CBR of 707.25 pixels (Figure 7A).
Miranda staining was completed and analyzed to compare Repo control to the
Pi3k; Repo X EGFR cross to explain glia overgrowth. Miranda staining can be seen in the
red stained cells showing successful staining of neuroblast stem cells (Figure 8).
Distribution of neuroblast cells, size and number were analyzed n the comparison.
Miranda staining, when compared to control and cross, revealed the cells in the cross are
not clearly or evenly distributed and vary in size. In the control, they are widely spaced
and similar in size across the CBR.

Drug screening in Pi3K EGFR model:
As mentioned, P1A9 and P1G10 had previously shown interesting effects on
tumor progression when examined with the Pten mutation via the RAS pathway. The
drug screen steps were the same between both mutations examined. These specific
tyrosine kinase inhibitors were tested on the Pi3K; Repo X EGFR mutation to determine
if the effects were similar for a different mutation. The size of the CBR in the Pteni;
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RasV12 mutation after drug exposure for three days showed enhancement from P1A9 and
suppression for P1G10 when compared to the Repo control (Figure 9).
P1A9 and P1G10 showed interesting effects on with the Pi3K; Repo X EGFR
mutation as well. The control when exposed to P1A9 for three days had CBR on average
of 460 pixels in width After 3 days of drug exposure, the cross on average exhibited a
CBR width of 928 pixels (Figure 10). In comparison, after three days of exposure to
P1G10, no larvae surfaced for the control drug vials. In addition, very few (3/20) larvae
rose across the 3 drug vials. Of the larvae surfaced and dissected, extremely fragile brain
lobes were observed in addition reduction in the CBR (Figure 11).

13

Figure 6
This figure shows the comparison between the studies of the two different mutations.
In both studies, the controls show a CBR of 140-170 pixels. In addition, in both
studies the activated mutations show a CBR 230 pixels.
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Figure 7
On average, the CBR was larger in the co-activated cross (A). This was analyzed from 4 brains in both
genotypes (B). The images were completed using fluorescent microscopy (C).
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Figure 8
Miranda staining is visible in the red stained neuroblast cells. The cross (right)
shows inconsistency in size, number and distribution of neurbolast cells when
compared to the Repo control.
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Figure 9
P1A9 showed enhancement of CBR through the Pteni; RasV12 mutation, whereas
P1G10 showed suppression of the tumor.
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Figure 10
P1A9 showed an increase in the width of the CBR in the cross when compared to the control.
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Figure 11
P1G10 had reduction in CBR in comparison to the
untreated control. The treated control had death of larvae
after exposure.
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Discussion
The increase in the width of the CBR in Pi3K; Repo X EGFR cross in comparison
to the control stock seen in Figure 6 in conjunction with results from Miranda staining
supported successful co-activation of the Pi3K pathway and EGFR pathway for
tumorigenesis. Further, the unequal distribution, increase in size and number of
neuroblast cells in the cross compared to the Repo control explains how tumor
progression may occur. An increase in number of neuroblast stem cells and unequal
distribution can result in greater number and unequal distribution of glia seen in glioma
tumors due to the asymmetric cell division these stem cells undergo. Determining
successful co-activation of these oncogenic pathways and successful tumor progression
was important before the tyrosine kinase inhibitor drugs were tested.
P1A9 and P1G10 showed interesting effects on tumor progression for the Pteni;
RasV12 mutation. P1A9 showed enhancement across the CBR, while P1G10 showed
suppression across the CBR. When these two drugs were examined with the Pi3K; Repo
X EGFR mutation, P1A9 showed similar results. Enhancement was seen across the CBR
after three days of exposure when compared to the control. However, P1G10 showed an
interesting response after drug exposure for this constitutively active mutation. P1G10
indicated possible suppression, as well as possible lethality. Larvae images were unable
to be obtained for the control, as larvae did not survive to day three following the
addition to the drug vials. In addition, the larvae dissected for the cross that arose in small
numbers had extremely fragile brains. The reduction in size of the CBR compared to the
untreated control images indicated possible suppression; however, the fragility and lack
of surviving larvae indicated possible lethality.
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Conclusion
In conclusion, this thesis project tested specific tyrosine kinase inhibitor drugs
that had shown interesting effects on a negative mutation, Pten, through the RAS
pathway on a constitutively active mutation of EGFR through the Pi3K pathway. The
critical first step of co-activating the EGFR and Pi3K pathway was successfully
accomplished through a series of crosses across three generations. The successful
genotype completion was seen through control images and Miranda staining. The two
specific tyrosine kinase inhibitor drugs tested were P1A9 and P1G10. P1A9 had shown
enhancement when tested on Pteni; RasV12 mutation. Enhancement was also observed
when P1A9 was tested on Pi3K; Repo X EGFR mutation. P1G10 had shown promising
suppression when tested on the Pteni; RasV12 mutation. P1G10 indicated possible
suppression when compared to the untreated control. Most importantly, P1G10 also
indicated possible lethality on this specific mutation. Future directions include retesting
P1G10 to examine this possible lethality and determine if suppression or lethality is
observed. In addition, other tyrosine kinase inhibitor drugs that had shown promising
effects on the original drug screen should be tested to further examine the Pi3K; Repo X
EGFR mutation. These specific drugs include P1A4, P1D2, P1D3, and P1D10.

21

Works Cited
Brennan, C.W., Verhaak, R.G., McKenna, A., Campos, B., Noushmehr, H., Salama,
S.R., Zheng, S., Chakravarty, D., Sanborn, J.Z., Berman, S.H., Beroukhim, R.,
Bernard, B., Wu, C.J., Genovese, G., Shmulevich, I., Barnholtz-Sloan, J., Zou, L.,
Vegesna, R., Shukla, S.A., Ciriello, G., Yung, W.K., Zhang, W., Sougnez, C.,
Mikkelsen, T., Aldape, K., Bigner, D.D., Van Meir, E.G., Prados, M., Sloan, A.,
Black, K.L., Eschbacher, J., Finocchiaro, G., Friedman, W., Andrews, D.W., Guha,
A., Iacocca, M., O'Neill, B.P., Foltz, G., Myers, J., Weisenberger, D.J., Penny, R.,
Kucherlapati, R., Perou, C.M., Hayes, D.N., Gibbs, R., Marra, M., Mills, G.B.,
Lander, E., Spellman, P., Wilson, R., Sander, C., Weinstein, J., Meyerson, M.,
Gabriel, S., Laird, P.W., Haussler, D., Getz, G., Chin, L., Network, T.R., 2013. The
somatic genomic landscape of glioblastoma. Cell155, 462-477.
Brody, Thomas B. “Miranda.” Miranda, The Interactive Fly, 1995,
www.sdbonline.org/sites/fly/neural/mirnda1.htm.
Brody, Thomas B. “Genes Involved in Tissue and Organ Development.” Drosophila
Tissue and Organ Development: Brain, The Interactive Fly, 1995,
www.sdbonline.org/sites/fly/aimorph/brain2.htm.
Boockvar, J.A., Kapitonov, D., Kapoor, G., Schouten, J., Counelis, G.J., Bogler, O.,
Snyder, E.Y., McIntosh, T.K., O'Rourke, D.M., 2003. Constitutive EGFR
signaling confers a motile phenotype to neural stem cells. Mol Cell Neurosci 24,
1116-1130.
Chien, S., Reiter, L.T., Bier, E., Gribskov, M., 2002. Homophila: human disease gene
cognates in Drosophila. Nucleic Acids Res 30, 149-151.
Fortini ME, Skupski MP, Boguski MS, Hariharan IK. A survey of human disease
gene counterparts in the Drosophila genome. J Cell Biol. 2000;150:F23–30.
Homem, Catarina C. F., and Juergen A. Knoblich. “Drosophila Neuroblasts: a Model for
Stem Cell Biology.” Development, Oxford University Press for The Company of
Biologists Limited, 1 Dec. 2012, dev.biologists.org/content/139/23/4297.

22
Huang, P.H., Mukasa, A., Bonavia, R., Flynn, R.A., Brewer, Z.E., Cavenee, W.K.,
Furnari, F.B., White, F.M., 2007. Quantitative analysis of EGFRvIII cellular
signaling networks reveals a combinatorial therapeutic strategy for glioblastoma.
Proc Natl Acad Sci U S A 104, 12867-12872.
John, Alphy et al. “Achiasmy: Male Fruit Flies Are Not Ready to Mix.” Frontiers in cell
And developmental biology vol. 4 75. 19 Jul. 2016,
doi:10.3389/fcell.2016.000752018, doi:10.1534/g3.118.200021
Liu, Aizhen et al. “Genetics and Epigenetics of Glioblastoma: Applications and Overall
Incidence of IDH1 Mutation.” Frontiers in oncology vol. 6 16. 29 Jan. 2016,
doi:10.3389/fonc.2016.00016
Miller, Danny E et al. “The Molecular and Genetic Characterization of Second
Chromosome Balancers in Drosophila melanogaster.” G3 (Bethesda, Md.) vol.
8,4 1161-1171. 28 Mar.
National Cancer Institute. (2018). Drugs Approved for Different Types of Cancer.
Retrieved July 22, 2018, from https://www.cancer.gov/aboutcancer/treatment/drugs/cancer-type
Paul, Manash K, and Anup K Mukhopadhyay. “Tyrosine kinase - Role and significance
in Cancer.” International journal of medical sciences vol. 1,2 (2004): 101-115.
doi:10.7150/ijms.1.101
Phillips, H.S., Kharbanda, S., Chen, R., Forrest, W.F., Soriano, R.H., Wu, T.D.,
Misra, A., Nigro, J.M., Colman, H., Soroceanu, L., Williams, P.M., Modrusa, Z.,
Feuerstein, B.G., Aldape, K., 2006. Molecular subclasses of high-grade glioma
predict prognosis, delineate a pattern of disease progression, and resemble stages
in neurogenesis.Cancer Cell 9, 157-173.
Raizer, J., 2011. Issues in developing drugs for primary brain tumors: barriers and
toxicities. Toxicol Pathol 39, 152-157.
Read, R.D., 2011. Drosophila melanogaster as a model system for human brain
cancers. Glia 59, 1364-1376.
Read, R.D., Cavenee, W.K., Furnari, F.B., Thomas, J.B., 2009. A drosophila model

23
For EGFR-Ras and PI3K-dependent human glioma. PLoS Genet 5, e1000374.
Read, R.D., Fenton, T.R., Gomez, G.G., Wykosky, J., Vandenberg, S.R., Babic, I.
Iwanami, A., Yang, H., Cavenee, W.K., Mischel, P.S., Furnari, F.B., Thomas, J.B.,
2013.A kinome-wide RNAi screen in Drosophila Glia reveals that the RIO kinases
mediate cell proliferation and survival through TORC2-Akt signaling in glioblastoma.
PLoS Genet 9, e1003253.
Tickoo, S., Russell, S., 2002. Drosophila melanogaster as a model system for drug
discovery and pathway screening. Curr Opin Pharmacol 2, 555-560.
Verhaak, R.G., Hoadley, K.A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M.D.,
Miller, C.R., Ding, L., Golub, T., Mesirov, J.P., Alexe, G., Lawrence, M.,
O'Kelly, M., Tamayo, P., Weir, B.A., Gabriel, S., Winckler, W., Gupta, S.,
Jakkula, L., Feiler, H.S., Hodgson, J.G., James, C.D., Sarkaria, J.N., Brennan, C.,
Kahn, A., Spellman, P.T., Wilson, R.K., Speed, T.P., Gray, J.W., Meyerson, M.,
Getz, G., Perou, C.M., Hayes, D.N., Cancer Genome Atlas Research, N., 2010.
Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma
characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell
17, 98-110.

